Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

Terence Hall · SciRah

Researcher profile · Semantic Scholar

Terence Hall

Share profile

Terence Hall — researcher profile on SciRah

h-index: 11
Works: 36
Citations: 924

Most-cited papers

Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
V. Mazzaferro, B. El-Rayes, Michele Droz Dit Busset, C. Cotsoglou +15 more
2018British Journal of Cancer329 citations Open access
Semantic Scholar
Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092
Yi Yu, R. Savage, S. Eathiraj, J. Meade +4 more
2015PLoS ONE111 citations Open access
Semantic Scholar
Discovery and optimization of a series of 3-(3-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amines: orally bioavailable, selective, and potent ATP-independent Akt inhibitors.
M. Ashwell, J. Lapierre, Christopher J. Brassard, K. Bresciano +28 more
2012Journal of Medicinal Chemistry98 citations Open access
Semantic Scholar
A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours
K. Papadopoulos, B. El-Rayes, A. Tolcher, A. Patnaik +11 more
2017British Journal of Cancer92 citations Open access
Semantic Scholar
Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation
Terence Hall, Yi Yu, S. Eathiraj, Yun-Xia Wang +4 more
2016PLoS ONE86 citations Open access
Semantic Scholar
Identifying and Overcoming Matrix Effects in Drug Discovery and Development
Terence Hall, I. Smukste, K. Bresciano, Yun-Xia Wang +2 more
201251 citations Open access
Semantic Scholar
ARQ 087, an oral pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced intrahepatic cholangiocarcinoma (iCCA) with FGFR2 genetic aberrations.
V. Mazzaferro, B. El-Rayes, C. Cotsoglou, W. Harris +14 more
201734 citations
Semantic Scholar
In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor
Yi Yu, Terence Hall, S. Eathiraj, M. Wick +2 more
2017Anti-Cancer Drugs28 citations Open access
Semantic Scholar
Antitumor Activity of a Novel Fibroblast Growth Factor Receptor (FGFR) Inhibitor for Intrahepatic Cholangiocarcinoma.
C. Raggi, Karim Fiaccadori, M. Pastore, M. Correnti +22 more
2019American Journal of Pathology20 citations Open access
Semantic Scholar
ARQ 087 inhibits FGFR signaling and rescues aberrant cell proliferation and differentiation in experimental models of craniosynostoses and chondrodysplasias caused by activating mutations in FGFR1, FGFR2 and FGFR3.
Lukas Balek, Iva Gudernova, I. Veselá, M. Hampl +9 more
2017Bone19 citations
Semantic Scholar
Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of ARQ 501 (beta-lapachone) in plasma and tumors from nu/nu mouse xenografts.
R. Savage, Terence Hall, K. Bresciano, J. Bailey +2 more
2008Journal of chromatography. B, Analytical technologies in the biomedical and life sciences16 citations
Semantic Scholar
PD-019ARQ 087, an oral pan- fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced and/or metastatic intrahepatic cholangiocarcinoma (iCCA).
V. Mazzaferro, W. Shaib, L. Rimassa, W. Harris +10 more
201611 citations Open access
Semantic Scholar
Phase 1, first-in-human study of ARQ 087, an oral pan-Fibroblast Growth Factor Receptor (FGFR) inhibitor, in patients (pts) with advanced solid tumors.
K. Papadopoulos, A. Tolcher, A. Patnaik, D. Rasco +7 more
201511 citations
Semantic Scholar
A pharmacokinetic and safety study of oral arsenic trioxide in patients with acute promyelocytic leukemia
F. Ravandi, Sravanti Rangaraju, H. Kantarjian, G. Garcia-Manero +11 more
2025Blood Advances5 citations Open access
Semantic Scholar
Phase 1/1b study of SY-5609, a selective and potent CDK7 inhibitor, in advanced solid tumors and in 2L/3L pancreatic ductal adenocarcinoma (PDAC) in combination with gemcitabine +/- nab-paclitaxel.
B. Bashir, Manish R Sharma, D. Juric, K. Papadopoulos +16 more
2023Journal of Clinical Oncology4 citations Open access
Semantic Scholar
Tolerability and preliminary activity of the potent, selective, oral CDK7 inhibitor SY-5609 in combination with fulvestrant in patients with advanced hormone receptor-positive (HR+), HER2- breast cancer (BC).
D. Juric, D. Richardson, B. Bashir, Manish R Sharma +10 more
2023Journal of Clinical Oncology2 citations
Semantic Scholar
Abstract LB-018: ARQ 531, a novel and reversible inhibitor of Bruton's tyrosine kinase, displays favorable oral bioavailability and exposure in patients with B-cell malignancies
Terence Hall, Yi Yu, S. Eathiraj, D. Stephens +4 more
2018Experimental and Molecular Therapeutics2 citations
Semantic Scholar
Abstract 374: In vitro and in vivo anti-tumor activity of ARQ 751, a potent and selective AKT inhibitor
Yi Yu, R. Savage, S. Eathiraj, Terence Hall +2 more
20162 citations
Semantic Scholar
Abstract 4797: In vitro and in vivo effect of ARQ 531 on Trk family kinases
Yi Yu, G. Schwartz, Pascal Schamber, R. Savage +3 more
2018Experimental and Molecular Therapeutics1 citations
Semantic Scholar
Abstract 4808: Combinations of imatinib mesylate with AKT inhibitor (miransertib, ARQ 751) or FGFR inhibitor (derazantinib) show synergy in GIST cell lines and preclinical models
M. Kozinova, Shalina Joshi, K. Devarajan, Phillip Zook +9 more
2018Experimental and Molecular Therapeutics1 citations
Semantic Scholar
Abstract B151: In FGFR2 driven tumors, preclinical pharmacokinetics (PK), pharmacodynamics (PD) and efficacy translate into clinical activity of ARQ 087
Terence Hall, R. Savage, B. Schwartz, Yi Yu +7 more
20151 citations
Semantic Scholar
145 ARQ 087, a novel pan FGFR-inhibitor crosses the BBB (blood–brain barrier) and distributes to the brain of rats
R. Savage, Terence Hall, B. Schwartz
20141 citations
Semantic Scholar
Abstract A034: The use of biomarkers and ctDNA in a phase 1 trial of ARQ 751
S. Pant, M. Lamar, J. Kazakin, R. Savage +2 more
2019Biomarkers0 citations
Semantic Scholar
Abstract 2943: In vivo combination of miransertib (ARQ 092) with anti-PD-1 antibody, trametinib, lapatinib, trastuzumab and paclitaxel
Yi Yu, Terence Hall, S. Eathiraj, R. Savage +1 more
2018Experimental and Molecular Therapeutics0 citations
Semantic Scholar
Abstract LB-232: Derazantinib (ARQ 087) pharmacodynamics: Alterations in FGF19/21/23 and phosphate in patients with cholangiocarcinoma
Terence Hall, V. Mazzaferro, B. El-Rayes, C. Cotsoglou +15 more
2018Clinical research0 citations
Semantic Scholar
Abstract 793: The novel Bruton's tyrosine kinase inhibitor ARQ531 disrupts survival signaling and triggers apoptosis in AML cells
S. Debora, S. Orecchioni, A. Cagnetta, V. Retali +12 more
2018Experimental and Molecular Therapeutics0 citations
Semantic Scholar
An investigation into fatty acid ethyl esters in mouse brains after ethanol treatment: detection, quantification, and potential toxicity
Terence Hall
20170 citations Open access
Semantic Scholar
Abstract B183: Targeting PI3K pathway dependent endometrial tumors with allosteric AKT inhibitors, ARQ 092 and ARQ 751
S. Eathiraj, B. Schwartz, Yi Yu, M. Wick +4 more
20150 citations
Semantic Scholar
Abstract CT319: Determination of FGF-19, 21, and 23 protein levels in a phase I clinical trial of ARQ 087, an oral pan-FGFR inhibitor
Terence Hall, J. Kazakin, B. Schwartz, R. Savage
20150 citations
Semantic Scholar
Abstract 3500: Combinations of ARQ087 with chemotherapeutic agents are safe and show a striking antitumor activity in different xenograft models
Rosaria Chilà, F. Guffanti, Terence Hall, F. Ricci +2 more
20150 citations
Semantic Scholar
389 A phase 1, dose-escalation, first-in-human study of ARQ 087, an oral pan-FGFR inhibitor, in adult subjects with advanced solid tumors
K. Papadopoulos, A. Tolcher, M. Kittaneh, A. Patniak +8 more
20140 citations
Semantic Scholar
Abstract C83: Nonclinical in vitro ADME, disposition, and pharmacokinetic assessment of ARQ 092, a selective AKT inhibitor.
Laurie P. Volak, K. Bresciano, Terence Hall, David Vensel +4 more
20130 citations
Semantic Scholar
Abstract C84: Nonclinical metabolism, disposition, pharmacokinetics, and in vitro drug-drug interaction assessment of ARQ 087, a pan-FGFR inhibitor.
Terence Hall, Laurie P. Volak, K. Bresciano, Yun-Xia Wang +5 more
20130 citations
Semantic Scholar
Abstract 3231: In vitro cross species metabolism of a novel RAF kinase inhibitor phosphate prodrug, ARQ 736
Terence Hall, K. Bresciano, Laurie P. Volak, Yun-Xia Wang +5 more
20110 citations
Semantic Scholar
Abstract 5783: In vitro ADME properties of ARQ 621: A specific Eg5 inhibitor
R. Savage, Cai-Yun Zhong, Terence Hall, K. Bresciano +3 more
20100 citations
Semantic Scholar
Pharmacokinetics of a novel PGA-ARQ 501 conjugate in mouse xenografts
R. Savage, Terence Hall, Manish Tandon, J. Lapierre +5 more
20070 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

R. Savage×21
Invite
R. Savage — researcher profile on SciRah
B. Schwartz×13
Invite
B. Schwartz — researcher profile on SciRah
Yun-Xia Wang×10
Invite
Yun-Xia Wang — researcher profile on SciRah
J. Kazakin×10
Invite
J. Kazakin — researcher profile on SciRah

×10

Invite

Yi Yu — researcher profile on SciRah

S. Eathiraj×10

Invite

S. Eathiraj — researcher profile on SciRah

G. Abbadessa×10

Invite

G. Abbadessa — researcher profile on SciRah

K. Papadopoulos×9

Invite

K. Papadopoulos — researcher profile on SciRah

Invite

B. Schwartz — researcher profile on SciRah

K. Bresciano×7

Invite

K. Bresciano — researcher profile on SciRah

Invite

B. El-Rayes — researcher profile on SciRah

Invite

W. Shaib — researcher profile on SciRah